The Neuroscience of Being Human

The Neuroscience of Cocaine

How dopamine transporter blockade produces the most reinforcing drug known to neuroscience, why the prefrontal cortex loses its authority, and what the crash, the withdrawal, and the primate recovery data reveal about the brain's capacity to repair

1,580-word article with 8 Harvard references.

The transporter blockade: what cocaine does in the synapse

Cocaine's mechanism of action is, by the standards of psychopharmacology, remarkably straightforward. It binds to the dopamine transporter and blocks it. The dopamine transporter is the protein embedded in the presynaptic membrane whose job is to vacuum dopamine out of the synaptic cleft after it has been released, terminating the signal and returning the neurotransmitter for recycling. When cocaine occupies this transporter, dopamine remains in the cleft, continuing to stimulate postsynaptic dopamine receptors long after the signal should have ended. The result is a sustained, amplified dopamine signal in the nucleus accumbens, the brain's principal reward processing centre (Ritz et al., 1987).

Volkow et al. (1997), using positron emission tomography in human volunteers, demonstrated that the relationship between DAT blockade and subjective experience is dose-dependent and quantifiable. When cocaine blocked fewer than forty-seven per cent of dopamine transporters, subjects reported no subjective high. When blockade exceeded this threshold, the intensity of the high correlated directly with the degree of transporter occupancy. The finding was important because it established that cocaine's reinforcing effects are not mysterious. They are a direct, measurable consequence of how much dopamine is prevented from being cleared. The brain is not responding to cocaine. It is responding to its own dopamine, which cocaine has prevented from being removed.

From voluntary to compulsive: the molecular switch

The first use of cocaine is voluntary. The hundredth use, in many cases, is not. The transition from choice to compulsion is one of the central questions in addiction neuroscience, and cocaine has been the model substance for studying it. Nestler (2005), writing in Nature Neuroscience, described the role of DeltaFosB, a transcription factor that accumulates in the nucleus accumbens with repeated drug exposure. Unlike most transcription factors, which are produced rapidly and degraded within hours, DeltaFosB is unusually stable. It builds up with each exposure and persists for weeks to months after the last dose. As it accumulates, it alters the expression of genes involved in synaptic plasticity, receptor density, and dendritic morphology, physically restructuring the reward circuitry to increase the motivational salience of drug-related cues.

The practical consequence is that the brain of a chronic cocaine user does not merely want cocaine. It has been molecularly reconfigured to prioritise cocaine-related stimuli above other rewards. The sight of powder, the smell of a particular environment, the company of particular people, these cues acquire a motivational potency that competes with and frequently overrides the signals from the prefrontal cortex that are attempting to say no. Goldstein and Volkow (2011) documented the other side of this equation. Chronic cocaine users show measurable reductions in prefrontal cortex metabolic activity, grey matter volume, and functional connectivity. The region of the brain responsible for impulse control, consequence evaluation, and behavioural inhibition is simultaneously weakened while the reward system driving drug-seeking behaviour is simultaneously strengthened. The person is not failing to exercise willpower. They are attempting to exercise willpower with a prefrontal cortex that has been structurally compromised by the very substance it is trying to resist.

Crack and powder: why route of administration changes everything

Cocaine hydrochloride, the powder form, is typically insufflated, absorbed through the nasal mucosa, and reaches peak brain concentration in three to five minutes. Crack cocaine, the freebase form, is smoked, absorbed through the pulmonary circulation, and reaches the brain in eight to ten seconds. The molecule is identical. The pharmacology at the transporter is identical. The difference is speed of onset, and in addiction neuroscience, speed of onset is not a minor variable. It is arguably the most important determinant of addictive liability (Hatsukami and Fischman, 1996).

The reason is associative learning. The brain's reward prediction system links cause and effect more tightly when the interval between them is short. A drug that produces its rewarding effect in ten seconds creates a stronger conditioned association than the same drug producing the same effect in five minutes. The consequence is that crack cocaine produces more rapid onset of compulsive use, more intense craving, shorter intervals between doses, and faster progression from initial use to dependence than powder cocaine. The legal distinction between the two forms, which for decades resulted in dramatically different sentencing in the United States, was always pharmacologically incoherent. The policy treated a difference in route of administration as though it were a difference in moral culpability. The neuroscience sees only a difference in the speed at which the same transporter blockade reaches the same nucleus accumbens.

The crash: what happens when the dopamine is gone

Gawin and Kleber (1986), studying cocaine abusers presenting for treatment, described a three-phase abstinence syndrome that remains the standard clinical model. Phase one is the crash: an acute period of exhaustion, hypersomnia, depression, and increased appetite that begins within hours of the last dose and lasts one to four days. The crash is the brain's immediate response to acute dopamine depletion. The transporter is no longer blocked. Dopamine is being cleared normally. But the presynaptic stores are depleted and the postsynaptic receptors, having been overstimulated, are downregulated. The result is a dopaminergic system that is simultaneously understocked and underresponsive.

Phase two is withdrawal proper: a protracted period of anhedonia, anxiety, irritability, and intense craving that can last one to ten weeks. During this phase, the brain is attempting to recalibrate its reward baseline. Activities that were previously pleasurable, food, social interaction, exercise, produce diminished dopamine responses because the system has been calibrated to the supraphysiological levels that cocaine provided. The world feels flat, grey, and unrewarding. Phase three is extinction, an indefinite period during which intermittent craving can be triggered by environmental cues associated with prior use. A person who has been abstinent for months can experience sudden, intense craving upon encountering a cue, a location, a person, a song, that the brain has associated with cocaine through prior conditioning. The craving is not a failure of recovery. It is evidence that the associative learning was effective and durable.

What cocaine does to the body through the brain

Cocaine's effects extend beyond the reward system. The sympathetic nervous system activation produced by norepinephrine and dopamine reuptake blockade causes vasoconstriction, tachycardia, and hypertension. Karila et al. (2014), reviewing the clinical complications, documented that cocaine is a leading cause of drug-related emergency department visits. Myocardial infarction can occur in young users with no prior cardiovascular disease because cocaine-induced coronary vasospasm can reduce blood flow to the heart muscle regardless of the condition of the coronary arteries. Stroke, both ischaemic and haemorrhagic, occurs at elevated rates in cocaine users due to the combined effects of hypertension, vasospasm, and impaired cerebrovascular autoregulation.

The neuropsychiatric complications are equally concerning. Cocaine-induced paranoia, which can reach psychotic intensity, reflects excessive dopaminergic activity in mesolimbic pathways. Cocaine-induced seizures reflect lowered seizure thresholds from kindling effects. The combination of cardiovascular toxicity, cerebrovascular risk, and neuropsychiatric instability means that cocaine carries acute medical risks with every use, not merely cumulative risks from chronic use. This distinguishes it from many other drugs of abuse, where the primary risks are chronic and dose-dependent. With cocaine, a single session of heavy use can produce a cardiac or cerebrovascular event in a person who was medically well that morning.